Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IM6T
|
|||
| Drug Name |
Tisagenlecleucel
|
|||
| Synonyms |
Tisagenlecleucel-T
Click to Show/Hide
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Approved | [1] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 3 | [2] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 3 | [2] | ||
| Follicular lymphoma [ICD-11: 2A80] | Phase 2 | [2] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Application submitted | [3] | ||
| Company |
Novartis Pharmaceuticals East Hanover, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | Immunostimulant | [1] |
| Leukocyte surface antigen Leu-16 (CD20) | Target Info | Immunostimulant | [3] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| PI3K-Akt signaling pathway | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | PIP3 activates AKT signaling | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | Human Complement System | |||
| Signaling by the B Cell Receptor (BCR) | ||||
| PIP3 activates AKT signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.